Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients.

Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Biomarkers, Tumor/*genetics ; Breast Neoplasms/*genetics ; Breast Neoplasms/*mortality ; Carcinoma, Ductal, Breast/*genetics ; Carcinoma, Ductal, Breast/*mortality ; Carcinoma, Lobular/*genetics ; Carcinoma, Lobular/*mortality ; Myelin Proteins/*genetics; Austria ; Biomarkers, Tumor/analysis ; Breast Neoplasms/pathology ; Carcinoma, Ductal, Breast/pathology ; Carcinoma, Lobular/pathology ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Membrane Glycoproteins/genetics ; Middle Aged ; Neoplasm Staging ; Prognosis ; Proportional Hazards Models ; Receptors, Estrogen/analysis ; Receptors, Estrogen/genetics ; Reproducibility of Results ; Retrospective Studies ; Reverse Transcriptase Polymerase Chain Reaction ; Risk Assessment ; Risk Factors ; Survival Rate ; Time Factors

Background: Gene expression of peripheral myelin protein 22 (PMP22) and the epithelial membrane proteins (EMPs) was found to be differentially expressed in invasive and non-invasive breast cell lines in a previous study. We want to evaluate the prognostic impact of the expression of these genes on breast cancer.
Methods: In a retrospective multicenter study, gene expression of PMP22 and the EMPs was measured in 249 primary breast tumors by real-time PCR. Results were statistically analyzed together with clinical data.
Results: In univariable Cox regression analyses PMP22 and the EMPs were not associated with disease-free survival or tumor-related mortality. However, multivariable Cox regression revealed that patients with higher than median PMP22 gene expression have a 3.47 times higher risk to die of cancer compared to patients with equal values on clinical covariables but lower PMP22 expression. They also have a 1.77 times higher risk to relapse than those with lower PMP22 expression. The proportion of explained variation in overall survival due to PMP22 gene expression was 6.5% and thus PMP22 contributes equally to prognosis of overall survival as nodal status and estrogen receptor status. Cross validation demonstrates that 5-years survival rates can be refined by incorporating PMP22 into the prediction model.
Conclusions: PMP22 gene expression is a novel independent prognostic factor for disease-free survival and overall survival for breast cancer patients. Including it into a model with established prognostic factors will increase the accuracy of prognosis.

Breast Cancer Res Treat. 1999 Jul;56(1):91-7. (PMID: 10517346)
Control Clin Trials. 1996 Aug;17(4):343-6. (PMID: 8889347)
Prog Nucleic Acid Res Mol Biol. 2000;64:97-129. (PMID: 10697408)
Tumour Biol. 2003 Aug-Sep;24(4):189-98. (PMID: 14654713)
Cancer Genet Cytogenet. 2003 Jan 15;140(2):162-6. (PMID: 12645656)
Neurochem Res. 2009 Jan;34(1):124-37. (PMID: 18481175)
Eur J Cancer. 2007 Mar;43(4):745-51. (PMID: 17257824)
Oncogene. 1990 Sep;5(9):1403-8. (PMID: 1699198)
J Histochem Cytochem. 2005 Jul;53(7):885-93. (PMID: 15995147)
Comput Methods Programs Biomed. 2003 Jun;71(2):155-63. (PMID: 12758137)
Biometrics. 2000 Mar;56(1):249-55. (PMID: 10783803)
Ann Oncol. 2007 Sep;18 Suppl 8:viii3-7. (PMID: 17890212)
BMC Cancer. 2008 Nov 21;8:339. (PMID: 19025599)
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. (PMID: 15761078)
J Neurosci Res. 1999 Dec 1;58(5):624-31. (PMID: 10561690)

0 (Biomarkers, Tumor)
0 (Membrane Glycoproteins)
0 (Myelin Proteins)
0 (PMP22 protein, human)
0 (Receptors, Estrogen)

Date Created: 20101217 Date Completed: 20110331 Latest Revision: 20211020

20221213

PMC3018461

10.1186/1471-2407-10-682

21159173